• Opinion
• [Reporter’s View] Keytruda’s ‘trade-off’ reimbursement
• by Eo, Yun-Ho Mar 7, 2022 05:49am

• Company
• Immuno-oncology drugs make ₩400 billion after 7 years
• by Mar 7, 2022 05:49am

• Company
• Organon is focusing on expanding the women's health lineup
• by Mar 7, 2022 05:49am

• Opinion
• [Reporter's view] Consistency in the post evaluation
• by Lee, Tak-Sun Mar 7, 2022 05:49am

• Company
• First RSA drug ‘Erbitux’ to receive second reevaluations
• by Eo, Yun-Ho Mar 4, 2022 05:57am

• Policy
• Brukinsa was approved using phase 2 data on MCL indications
• by Lee, Hye-Kyung Mar 4, 2022 05:57am

• Policy
• Janumet's salt change consigned drug have been approved for
• by Lee, Hye-Kyung Mar 4, 2022 05:57am

• Company
• ↓↓Sales of smoking cessation txs by 75% in 4 yrs
• by Ji Yong Jun Mar 4, 2022 05:56am

• Company
• Kyowa Kirin·Boryung to copromote sale of 2 neutropenia txs
• by Chon, Seung-Hyun Mar 4, 2022 05:55am

• Company
• Saxenda and Qsymia tops the growing obesity market
• by Chon, Seung-Hyun Mar 3, 2022 06:01am